
Rubella is an acute, viral, and contagious infection, which has a mild effect on children, and is caused by the transmission of airborne droplets of infected people through sneezing or coughing. However, pregnant women suffering from rubella have to face severe consequences, as the viral infection results in death or congenital defects known as congenital rubella syndrome (CRS).Rubella Vaccine Market has gained traction over the years as the disease is preventable only through vaccination and no other specific treatments exist for it. The major factors that fuel the growth of the market are increase in incidence of rubella infection globally Approximately 100,000 infants are affected by rubella annually, thus increasing the government focus on rubella vaccination, which further propels the market growth. However, inherent disadvantages of using human diploid cell technology for constructing rubella vaccine such as, high selectivity and insufficient yield, restrain the growth of market. Conversely, ongoing R&D activities for the advancement of rubella vaccines are expected to offer lucrative opportunities for the growth of the market.